Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-17

Clinical Trial Update: Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) [Phase 2]

View source ↗

Summary

Phase 2 dose-finding trial of GSK2248761 in antiretroviral therapy-naive HIV patients was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK2248761 (GSK2248761)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 2 | Status: TERMINATED | Results posted: 2017-11-17